Kymera Therapeutics Inc (KYMR) Stock Analysis
Verdict: HOLD
Accelerated STAT6 clinical timelines validate the Pegasus platform's speed, yet heavy insider selling and 186x P/S warrant caution.
Investment score: 64/100
Analysis as of
Is Kymera Therapeutics Inc stock worth reviewing? AI model thesis
Hold on clinical acceleration; wait for technical consolidation before adding.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Kymera Therapeutics Inc opportunities and risks
What speaks for KYMR
- KT-621 Clinical Acceleration
What speaks against KYMR
- Binary Clinical Results Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KYMR | n/a | 186.1x | n/a | 100.0% | -612.2% | -2.5% |
| SMMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.6% |
| KRYS | 46.4x | 25.4x | 50.4x | 92.8% | 53.9% | 2.2% |
| CYTK | n/a | 95.0x | n/a | 90.3% | -784.0% | -5.5% |
| APGE | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
| NUVL | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
Frequently asked questions about Kymera Therapeutics Inc (KYMR)
Is KYMR stock a good investment?
The cached TradeMates AI model rates Kymera Therapeutics Inc as HOLD with an investment score of 64/100. Hold on clinical acceleration; wait for technical consolidation before adding. This is algorithmic model output, not personal investment advice.
Is KYMR stock a buy?
The TradeMates model verdict for KYMR is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.